NanoString Technologies announced the launch of the latest assay for the GeoMx® Digital Spatial Profiler (DSP). The GeoMx IO Proteome Atlas (IPA) is the industry?s most comprehensive spatial proteomics assay, enabling spatial profiling of more than 500 immuno-oncology (IO) relevant targets from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue sections. Containing IHC-compatible antibodies entirely from abcam?s extensive IO portfolio, the GeoMx IPA provides an extraordinary advancement in the field of spatial proteomics.

The assay will provide researchers with more than five times the content of any competing panel, offering access to unprecedented power. Its utility is applicable to the search for novel biomarkers and drug targets, investigating therapeutic response, stratifying patients, and determining drug mechanisms of action. The combination of NanoString?s GeoMx IPA and WTA offers researchers unprecedented levels of data in the largest ever spatial proteomic panel of its kind.

The panel leverages the unique capabilities of GeoMx DSP to non-destructively and quantitatively profile protein expression over five logs of dynamic range in distinct compartments such as the tumor, stroma, and immune contexture. Researchers can run GeoMx IPA as a standalone assay or in conjunction with GeoMx WTA and can even layer GeoMx IPA data with previously collected WTA data to easily analyze the two datasets. The launch of the GeoMx IPA is the latest development in a long-standing collaboration between NanoString and abcam to provide high-quality, validated antibodies for use with NanoString?s spatial analysis platforms. Most recently, NanoString and abcam announced the inclusion of abcam-validated antibodies in the first 64-plex panel for NanoString?s CosMx?

Spatial Molecular Imager. Although the content is targeted for IO research, GeoMx IPA has broad applicability beyond cancer, including research areas such as infectious disease, organ transplant, autoimmunity, metabolism, and epigenetics. The GeoMx IPA assay can enable researchers to: Spatially profile FFPE tissue using over 500 of abcam?s IHC-validated IO antibodies in a single assay, simplifying the search for new protein biomarkers and drug targets with unrivaled plex.

Antibodies can also be used individually for further single target or lower plex investigation. Obtain more comprehensive biological information from precious tissue samples than traditional immunohistochemistry (IHC) or immunofluorescence (IF) assays. Discover novel IO drug targets by profiling the expression of over 500 protein targets from a single FFPE tissue section.

Profile the whole human transcriptome and IO proteome from a single slide by combining GeoMx IPA with GeoMx WTA for same-slide spatial proteogenomic analysis. The GeoMx IPA assay is available now for pre-order with shipments expected to begin in fourth quarter 2023.